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Background: Wireless capsule pH-metry (WC) is better tolerated than standard nasal pH catheter (SC), but
endoscopic placement is expensive. Aims: to confirm that non-endoscopic peroral manometric placement of WC is
as effective and better tolerated than SC and to perform a cost analysis of the available esophageal pH-metry
methods.
Methods: Randomized trial at 2 centers. Patients referred for esophageal pH testing were randomly assigned to WC
with unsedated peroral placement or SC after esophageal manometry (ESM). Primary outcome was overall
discomfort with pH-metry. Costs of 3 different pH-metry strategies were analyzed: 1) ESM+ SC, 2) ESM+WC and 3)
endoscopically placed WC (EGD+WC) using publicly funded health care system perspective.
Results: 86 patients (mean age 51 ± 2 years, 71% female) were enrolled. Overall discomfort score was less in WC
than in SC patients (26 ± 4 mm vs 39 ± 4 mm VAS, respectively, p = 0.012) but there were no significant group
differences in throat, chest, or overall discomfort during placement. Overall failure rate was 7% in the SC group vs
12% in the WC group (p = 0.71). Per patient costs ($Canadian) were $1475 for EGD+WC, $1014 for ESM+WC, and
$906 for ESM+ SC. Decreasing the failure rate of ESM+WC from 12% to 5% decreased the cost of ESM+WC to
$991. The ESM+ SC and ESM+WC strategies became equivalent when the cost of the WC device was dropped
from $292 to $193.
Conclusions: Unsedated peroral WC insertion is better tolerated than SC pH-metry both overall and during
placement. Although WC is more costly, the extra expense is partially offset when the higher patient and caregiver
time costs of SC are considered.
Trial registration: Clinicaltrials.gov Identifier NCT01364610
Keywords: Esophagus, Gastroesophageal reflux disease, pH-metry, Clinical trialBackground
Gastroesophageal reflux disease (GERD) is a common
disorder defined as mucosal damage or typical symptoms
produced by the abnormal reflux of gastric contents into
the esophagus [1]. Ambulatory esophageal pH monitoring
(pH-metry) is the established standard method for the diag-
nosis of GERD. Two methods are commercially available
for esophageal pH-metry: standard catheter (SC) and wire-
less capsule (WC).* Correspondence: motility@ucalgary.ca
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reproduction in any medium, provided the orStandard catheter pH-metry involves the placement of a
thin tube with one or more pH probes through the patient’s
nose to 5 cm above the lower esophageal sphincter (LES),
with the external end connected to a data recorder worn on
the body [1]. The catheter is then left in situ for 24 hours.
Although SC remains the most commonly used method for
evaluating GERD, it has significant limitations. Patients
often experience discomfort and embarrassment during SC
testing leading them to alter their usual daily activities in-
cluding their normal eating, drinking, and sleeping patterns.
Patients also frequently decrease their physical activity.
These lifestyle changes may reduce reflux events leading toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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although SC is relatively inexpensive, most patients feel they
cannot work during the testing period increasing the costs
borne by patients [3].
The WC method (Bravo™ System, Given Imaging,
Yoqneam, Israel; formerly produced by Medtronic Inc.,
Minneapolis, USA) uses wireless telemetry technology elim-
inating the need for a transnasal catheter. The small capsule
with an embedded pH probe is affixed to the distal esopha-
geal mucosa which conveys signals to a receiver/recorder
worn on the body [4]. Wireless capsule placement can be
performed endoscopically or manometrically and data can
be collected for 48 hours or longer.
Wireless capsule has been shown to be safe [1] and as
sensitive as SC for acid detection [5-7]. Furthermore, the
lack of a transnasal catheter permits patient to continue
their usual daily activities without impediment. However,
WC also has some disadvantages. The sedation used during
the standard endoscopic placement technique may affect
the accuracy of the data collected during the first 24 hours
[8,9]. Endoscopy also increases patient risk (due to the low
but measurable risk of perforation, bleeding, or adverse
reactions to sedation used) and increases the cost of the
procedure. Consequently, other groups have evaluated the
potential for trans-oral placement using manometry to
locate the LES. A technical problem with this approach is
that the esophageal manometry catheter is typically placed
transnasally making precise location of the LES via a trans-
oral approach potentially inaccurate. Lacy and colleagues
validated a correction factor of 4 cm allowing for accurate
placement of a transoral capsule [10]. They also determined
that trans-oral placement was effective and well tolerated by
patients. However, this was a non-randomized study and
thus confounding by assignment bias may have overesti-
mated the tolerability of manometric placement. Finally, al-
though a cost analysis on endoscopically-placed WC has
been performed [11], no study has assessed this question
with transoral placement or from the perspective of a
publicly funded health care system where time costs to
patients and caregivers should be considered [12].
Our study had two aims. The first was to confirm that
non-endoscopic peroral manometric placement of WC is
as effective and better tolerated than SC using a rando-
mized study design. Secondly, we performed a cost ana-
lysis of the available ambulatory esophageal pH
monitoring techniques, including endoscopic WC place-
ment (which was not assessed in this clinical trial). The
data from the clinical study and the published literature
were used to inform the cost analysis.
Methods
Study design
This was a dual center, randomized, non-blinded
study. Patients referred for pH-metry for investigationof persistent symptoms possibly related to GERD were
randomly assigned to standard trans-nasal catheter
(SC) or wireless capsule (WC) pH testing using unse-
dated peroral placement. The study was performed at
two regional motility centers in Alberta, Canada
(Rockyview General Hospital, Calgary and University
of Alberta Hospital, Edmonton). Participants in the
WC arm were studied for either 24 hours (Calgary) or
48 hours (Edmonton). This approach was used so that
a directly comparable timeframe of WC to standard
SC testing (i.e. 24 hours) as well as usual WC practice
(i.e. 48 hours) to standard SC practice were studied.
All patients had traditional esophageal manometry to
determine the distance to the LES. The study protocol
was approved by the Health Research Ethics Boards of
the Universities of Calgary and Alberta (registered at
clinicaltrials.gov NCT01364610). Written and oral
informed consent was obtained from all participants
before they entered the study. The trial was per-
formed in accordance with the International Confer-
ence on Harmonization of Good Clinical Practice
guidelines, which have their origins in the Declaration
of Helsinki.
Patient population
Patients aged 18–75 years referred for ambulatory pH
testing between August 2008 and August 2009 were
approached for enrollment into the study. Patients
with previous esophageal surgery (e.g. fundoplication,
myotomy) or achalasia were excluded. Once enrolled,
patients were randomly assigned to SC or WC.
Randomization schedules were generated in advance
in random blocks of 2 or 4, separately for each site
(PROC PLAN, SAS 9.2, Cary, NC) and in separate
envelopes. No stratification was used. Assignments
were not blinded, but patients and investigators were
not informed of their assignment until after the man-
ometry on the day of the test. Patients who declined
the study were provided standard care with SC pH-
metry. Patients were not remunerated for participat-
ing. No enrolled patients dropped out or withdrew
their consent. Recruitment was stopped after both
sites had completed 20 WC and 20 SC studies.
The primary endpoint was the overall discomfort
reported during WC versus SC pH-metry. Secondary end-
points included the success rates of probe placement, the
site-specific discomfort of the manometry and pH probe
placement procedures, the ability to perform usual
activities, and the time off work between groups. Failure
was defined as the inability to obtain a minimum of 20
hours of pH recording, and was subdivided into technical
causes (e.g. equipment malfunction), and patient causes (e.
g. inability to tolerate the insertion or ambulatory compo-
nent of the pH probe).
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Transnasal esophageal manometry (ESM) was performed in
all patients according to standard procedures [13,14], with
characterization of LES and esophageal function. Topical
nasal anesthesia with viscous lidocaine was used.
pH-metry
Standard Catheter (SC). After manometry, a calibrated
standard antimony-based pH catheter (Comfortec Plus
catheter and ZepHr Sleuth recorder, Sandhill Scientific,
Inc., Highlands Ranch, CO) was inserted trans-nasally to
5 cm above the proximal border of the LES, affixed to
the nose, and connected to the data recorder.
Wireless Capsule (WC). After topical pharyngeal
anesthesia, the activated and calibrated WC (Bravo™ wire-
less pH capsule system, Medtronic Inc., Minneapolis MN)
was inserted by mouth using the single-use Delivery System
to 5 cm above the proximal border of the LES. To convert
the distance from the naris (obtained at manometry) to the
distance from the incisors for peroral WC placement, a
conversion factor of 4 cm was subtracted [10]. WC was
deployed as per the manufacturer’s instructions. Briefly, suc-
tion was applied to the delivery system at a stable pressure
of approximately 500 mmHg for 30-60 seconds to bring the
esophageal mucosa into the suction well, then a spring-
loaded pin was deployed within the suction well to affix the
capsule. The delivery catheter was then removed.
After probe placement in both cases, responsiveness to
weakly acidic liquids (apple juice) was ascertained on the
data recorder in real time. Specific symptom events were
recorded by pushing buttons on the recorder and using a
written diary. After the study, the SC was removed. The
WC detaches spontaneously, typically after 5–7 days,
and passes out in the stool. The pH study results were
evaluated using standard composite scores provided with
the respective analysis software.
Questionnaires
Each patient completed a short symptom questionnaire
following pH probe placement and a second short question-
naire 24–48 hours later when they returned to complete
the test. Patients in the 24 hour study in Calgary were add-
itionally contacted after the study to assess the effect of the
test on their work patterns. Assessment of discomfort levels
was done using a 10 cm visual analog scale (VAS) [15] after
the manometry, after the device placement and after the pH
study period was completed.
Sample size and statistical analysis
The study was independently powered at both sites
(>80%) to show a significant difference in the primary
outcome measure with a minimum 20 patients per group
based on overall discomfort on a 10 cm VAS scale simi-
lar to that done in a previous study [16]. The minimumclinically important difference for changes for patient-
rated acute pain on this VAS scale is between 9 and
13 mm [17-19]. Normally distributed means were com-
pared using Student t-test and count data were com-
pared using Pearson Chi-square with continuity
correction, or Fisher Exact test where cell counts were 5
or less. A p-value< 0.05 was used to assess significance.
All tests were two-tailed.
Cost analysis
We performed a cost analysis of 3 different strategies for
obtaining esophageal pH-metry: 1) ESM+SC, 2) ESM
guided WC (ESM+WC) and 3) endoscopically placed
WC (EGD+WC). A decision tree was constructed using
decision analysis software (TreeAge Pro Suite 2009,
Williamstown, MA, USA) and is depicted in Additional
file 1: Figure S1. The perspective of the base case analysis
was that of the publicly funded health care system. Given
the short time horizon of the analysis (24 hours), no dis-
counting was performed.
Model inputs
The initial success rates for ESM+WC and ESM+SC
based on our trial results were 88% and 93%, respectively.
A 95% initial success rate for EGD+WC was assumed
from published studies in the recent literature, which
range from 90 to 100 percent [3,5,10,20,21]. In the EGD+
WC strategy we assumed that a second WC would be suc-
cessful in those where the first attempt failed. In this study
a second attempt was successful in both the ESM+WC
and ESM+SC strategies for those willing to undergo a re-
peat procedure (80% and 33%, respectively). Further detail
regarding the placement and insertion failures are found
below.
In the base case analysis, costs were those relevant to a
publicly funded health care system and thus included
patient and caregiver time costs in keeping with Canadian
guidelines [12]. Also consistent with contemporary guide-
lines and the perspective of the publicly funded health care
system, costs resulting from lost productivity were not con-
sidered. Thus costs resulting from reduced work capacity
due to illness and costs borne by employers to hire and
train replacement workers for patients during absences
were not included. Based on our study findings, we
assumed that 100% of patients in the ESM+SC strategy
would choose not to work in contrast to the ESM+WC
strategy where 93% of patients would have worked during
the testing period (see Results). However, we assumed that
patients would need 2 hours off work for the procedure in
the ESM+WC strategy. For those in the EGD+WC
strategy we assumed that patients would not return to work
until the next day given the sedation. Furthermore, it was
assumed that a companion would be required for a total of
4 hours to drive the patient to and from the appointment
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the average hourly wage rate ($22.50 per hour) published
for Albertans in 2010 as was done in a previous study [22].
The direct costs of each of the procedures included the
non-physician costs (capital, nursing, drugs, cleaning costs,
etc.) which we obtained from the Alberta Health Services -
Calgary Zone costing database [23] and the physician con-
sultant and procedural fees for the procedures. The cost of
WC was provided by the manufacturer. All costs are
reported in 2010 Canadian dollars. A summary of the input
values used in the decision tree is shown in Table 1.
Sensitivity analyses were performed. In addition we
examined a scenario where patient and caregiver time
costs were excluded.Results
A total of 86 patients had esophageal manometry and were
enrolled in the study (46 in Calgary and 40 in Edmonton).
There were no significant differences in the baseline
characteristics or variables tested between the two study
sites (data not shown) and thus the data presented in the
following tables are the pooled results for both sites. There
were no significant differences between the SC and WCTable 1 Cost Analysis: Base-case Input Variables





















EGD, esophagoduodenoscopy; ESM, esophageal manometry; SC, standard pH
catheter; WC, wireless pH capsule.
* 2nd attempt failures due to patients not wanting the test repeated.
Total cost EGD+WC= $1,445.72
Total cost ESM+WC= $974.69
Total cost ESM+ SC= $905.29groups in age, indication for testing, or manometry results
(Table 2). Although there was a trend toward more females
in the WC group, this did not reach statistical significance.
Manometry and pH probe placement
The manometric assessment was well tolerated by both SC
and WC groups, with no significant differences in overall or
site-specific discomfort (Table 3). The placement of the SC
probe was more uncomfortable in the nasal region com-
pared to WC (36±4 mm in the SC group compared to
6±2 mm in WC, p< 0.001), but there were no significant
differences in throat, chest, or overall discomfort between
the groups during placement. The time required for the
combined manometry and pH probe placement was not
significantly different between groups (Table 2).
pH study discomfort
At the completion of the pH assessment, the overall dis-
comfort score was less in the WC group than the SC group
(26±4 mm vs 39±4 mm, respectively, p=0.012; Table 3).
The nasal and throat discomfort scores were lower, but the
chest discomfort scores were higher in the WC group com-
pared to the SC group (Table 3). Patients in the WC group
were better able to eat and drink without difficulty and also
reported being more likely to undertake their regular daily
activities (p< 0.001 for both). Finally, those in the WCTable 2 Patient demographics
Variable SC Group WC Group P value
n= 43 n=43
Female (%) 26 (60) 35 (81) 0.057
Age (mean years ± SE) 49 ± 2 52± 2 0.328
Indication for Testing (%) 0.831
Reflux Symptoms 30 (70) 33 (77)
Chest Pain 8 (19) 7 (16)
Dysphagia 4 (9) 2 (5)
Other 1 (2) 1 (2)
Total Procedure Duration (manometry 53 ± 4 62± 8 0.339
and pH probe insertion, minutes ± SE)
Manometry Result (%) 0.377
Normal 12 (29) 17 (44)
Low LES resting pressure 18 (43) 12 (31)
IEM 7 (17) 8 (21)
Spastic (DES/nutcracker) 3 (7) 2(5)
Other 2 (5) 0 (0)
pH Results at Completion
Elevated Esophageal Acid Exposure* 24 (56) 19 (44) 0.388
*Based on standard composite scores. Cutoff for SC: Johnston/DeMeester,
normal score <22. Cutoff for WC: DeMeester, normal score <14.7. DES, diffuse
esophageal spasm; IEM, ineffectual esophageal motility; LES, lower esophageal
sphincter; SE, standard error; SC, standard pH catheter; WC, wireless pH
capsule.
Table 3 Grouped Outcomes
Variable SC Group WC Group P value
n= 43 n= 43
Manometry Discomforta
(mm VAS± SE)
Nasal 40 ± 3 33 ± 4 0.320
Throat 40 ± 3 34 ± 3 0.165
Chest 15 ± 3 14 ± 3 0.738
Overall 39 ± 3 34 ± 3 0.285
pH Placement Discomforta
(mm VAS± SE)
Nasal 36 ± 4 6± 2 <0.001
Throat 37 ± 3 32 ± 4 0.317
Chest 13 ± 3 14 ± 3 0.968
Overall 33 ± 3 29 ± 4 0.406
pH Test Discomforta
(mm VAS± SE)
Nasal 39 ± 3 10 ± 3 <0.001
Throat 43 ± 4 19 ± 4 <0.001
Chest 14 ± 3 29 ± 4 0.001
Overall 39 ± 4 26 ± 4 0.012
Eating and Drinking (mm VAS± SE, 51 ± 4 75 ± 5 <0.001
100 = completely normal)
Ability to do Usual Activities (mm 75± 5 92 ± 2 <0.001
VAS± SE, 100 = completely normal)
Would you Repeat the Test Again? 51 88 <0.001
(% Yes)
a100 =worst discomfort. SE, standard error; SC, standard pH catheter; WC,
wireless pH capsule; VAS, visual analogue scale.
Table 4 Initial Failures - Reasons and Rates
SC Group WC Group P
n=43 n=43 value
Total Failed (%) 3 (7) 5 (12) 0.713
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procedure again (88% vs 51%, p< 0.001). The proportion of
pH studies showing increased acid exposure was not signifi-
cantly different between the groups (Table 2).
Very few patients attempted to perform their usual work
activities during the pH study (data not shown). Since
subjects were not aware of their assignment until the day of
the procedure, most planned in advance to take the day off
work. However, when surveyed after the pH study none of
the patients in the SC group felt they could have performed
their regular work duties. In contrast, 93% of the patients in
the WC group reported that they would have continued
their usual daily routine including going to work
(p< 0.0001).Equipment Malfunction 1 (2) 2 (5)
Immediate Detachment (<1 hour) 1 (2)
Premature Detachment 1 (2)
Could not tolerate peroral insertion 1 (2)
Could not tolerate transnasal catheter 2 (5)
(self-removal)Failure rates
Three of 43 (7%) studies were unsuccessful in the SC group
(1 equipment malfunction after the patient dropped the re-
corder and 2 patients were unable to tolerate the indwelling
nasal pH catheter with subsequent early probe removal). Inthe WC group, 5 of 43 (12%) of studies were unsuccessful
(2 capsules failed to calibrate, 2 capsules detached early, and
one patient did not tolerate peroral insertion of the WC
due to excessive gagging and anxiety) (Table 4). The 2 early
detachments occurred within the first 5 WC studies that
were performed. The overall failure rates were not different
between the groups (p=0.713).Cost analysis
The data reported in Table 5 represent the expected total
cost to obtain 24-hour pH-metry per patient. Under the
base case assumptions the endoscopically placed WC
strategy was the most expensive strategy at $1475 per
patient whereas the standard ESM+SC was the least
costly at $906 per patient. The manometrically placed
WC strategy (ESM+WC) was $1014 per patient or $108
more than ESM+SC (Table 5).
In a sensitivity analysis we decreased the failure rate of
ESM+WC from 12% to 5% which decreased the cost of
ESM+WC to $991 and further dropped it to $981 with
a 2% failure rate (Table 5). If the work absenteeism in
the ESM+SC group was decreased from 100% to 90%
during the test, the cost of ESM+SC decreased to $888.
In a threshold analysis using the base case assumptions,
the SC and ESM+WC strategies became equivalent
when the cost of the WC device was dropped from $292
to $193 (Table 5). When patient and caregiver time costs
were excluded the expected costs of EGD+WC, ESM+
WC and ESM+SC were $1,155.80, $968.60 and $726,
respectively.Discussion
The results of this first randomized trial confirm that 24
hour pH-metry using unsedated peroral WC insertion is
better tolerated than SC both overall and during place-
ment. As expected, nasal and throat discomfort was
prominent in the SC group, while chest discomfort was
higher in the WC group during the pH monitoring
period. Furthermore, in keeping with previous reports on
WC, our findings suggest that the majority of patients
undergoing WC would choose to continue their regular






ESM+WC with 2% failure 981.32
ESM+WC with 5% failure 991.26
ESM+WC with 15% failure 1024.39
ESM+ SC with 90% absenteeism 887.97





EGD, esophagoduodenoscopy; ESM, esophageal manometry; SC, standard pH
catheter; WC, wireless pH capsule.
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none reported being capable of working. Lastly, although
WC is more costly than SC, our cost analysis shows that
the extra expense of WC is partially offset when the
higher patient and caregiver time costs of SC are
considered.
Since SC and WC appear to be equally effective in diag-
nosis of abnormal reflux when the procedure is successful,
failure rates thus become a key measure of effectiveness.
The 12% overall failure rate of WC in the present study falls
within the range of that reported in the literature [5,10,24],
although a recent series reported a failure rate of only 2%
[20]. The 5 WC failures that we encountered resulted from
2 capsule calibration errors (equipment failure), 1 patient
who could not tolerate placement of the capsule (patient in-
tolerance) and 2 early capsule detachments. Both of the
WC early detachments occurred near the start of the trial.
Although the investigators did have some prior experience
with WC at the start of the study, it is certainly possible that
the early detachments reflect the learning curve of the tech-
nique. However, it should also be noted that this study ran-
domized patients prospectively which previous case series
did not; since previous large series of WC did both endo-
scopic and unsedated transoral placements [10,21], patients
who felt unable to tolerate unsedated placement presum-
ably opted for endoscopic placement with sedation. That
approach will underestimate failure rates from a patient in-
tolerance standpoint, and thus the approach used in this
study is more applicable to situations where endoscopic
placement is not available. Although this study was not
designed to evaluate the 4 cm nose-to-mouth conversion
factor determined by Lacy et al. [10], there were no gross
misplacements of WC judged either clinically or according
to the pH study results using this method. Therefore, thisrelatively non-invasive technique is easy to learn and per-
form and is as reliable as SC for the ambulatory collection
of esophageal pH data.
Placement of WC without need for direct visualization
via gastroscopy is an important development. Endoscopy
is resource intensive, carries risks to patients and the
sedation that is generally required may alter the results
during the first 24 hours of pH monitoring [9,10,25].
Furthermore, patients can’t drive or work after receiving
sedation, which increases the patient-borne costs of the
procedure. We have shown that this is also a significant
problem for SC given that none of the patients in the SC
group reported being capable of going to work while the
catheter was in place. While there are some motivated
patients in the community who choose to work with a
SC in place, these are a small minority. In contrast, over
90% of those in the WC group would have chosen to re-
turn to work.
The results of our cost analysis demonstrate that peroral
WC (ESM+WC) is more costly than ESM+SC, but less
expensive than WC placed via gastroscopy (EGD+WC).
However, the incremental cost of ESM+WC over ESM+
SC drops when one takes into consideration the increased
patient and caregiver time costs associated with SC. When
time costs were excluded the incremental cost of ESM+
WC over ESM+SC was $243 compared to $108 when
these costs were included. Furthermore, had our failure rate
been only 5% instead of 12%, the incremental cost of ESM+
WC over ESM+SC would be $85 instead of $108. Our
post procedure questionnaire suggests that patients prefer
WC over SC given that nearly 90% would agree to have it
repeated if necessary compared to only half of those who
received SC. Therefore, given that patients prefer WC, can
continue their usual daily activities and can continue to
work during the ambulatory testing period, the added cost
of WC may be something that health jurisdictions should
consider. Like many technologies, the cost may drop over
time. We have shown that WC would be cost neutral if the
cost of the device were dropped to $193.
Our study has a number of limitations. Although the
study was powered to assess the overall patient experience
with pH placement and 24–48 hours of testing, the sample
size may have been too small to detect significant
differences in infrequent secondary outcomes such as
failure rates. However, the failure rates did match those in
the literature, and were subjected to sensitivity analysis in
the cost analysis. Second, the VAS scales used to assess dis-
comfort have not been validated specifically for manometry
or pH testing, and thus may not accurately capture all
dimensions of the pH testing experience. They are, however,
generally accepted measures for pain [15], and have been
used in the pH-metry literature previously [16]. With regard
to the cost analysis, the costing model was based on a num-
ber of assumptions which may not be accurate for all
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cost analyses. To account for the uncertainty in our model
estimates we performed sensitivity analyses to test how
changes in our model inputs affected our results. Finally, we
assumed that SC and WC have equivalent effectiveness for
diagnosis of GERD. Typically, WC studies are performed
for 48 hours in clinical practice, and this extra data may im-
prove sensitivity for detection of abnormal acid exposure
[5]. However, there is no consensus as to whether this
improves the effectiveness of the technology, but WC does
not appear to be less sensitive than SC [5-7]. We thus took
a conservative approach based on the assumption that the
technologies were equivalent.
The major limitation of WC pH-metry is the pH meas-
urement from only one site. SC typically has a proximal
pH sensor as well, which provides more data, although
does not affect composite score calculation and subse-
quent determination of abnormal acid exposure. With
the advent of new technologies such as multichannel intra-
luminal impedance with pH (MII-pH), even more data is
available to analyze all refluxate regardless of pH. This
becomes increasingly important in the post-proton pump
inhibitor (PPI) era, where the majority of pH investigations
are done for atypical symptoms or PPI failure. The exact
role of WC pH-metry in the stable of diagnostic tools for
reflux disorders has yet to be fully determined, but will
likely be the modality of choice for confirmation of acid
reflux, for example prior to fundoplication.
Conclusions
This randomized study adds to the growing body of litera-
ture that WC pH testing is clearly more acceptable to
patients compared to SC-based methods. Until recently the
increased cost, especially associated with endoscopy, has
limited the uptake of WC in publically-funded health
systems. However, unsedated peroral placement of WC is
simple, effective, and as well tolerated as transnasal place-
ment of a SC. Following WC placement, patients can re-
sume their usual activities and return to work which is a
significant advantage over SC. Lastly, although WC is more
costly than SC, health jurisdictions should take into
consideration that patient borne costs of WC are lower and
that patients strongly prefer WC over SC.
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